IN2012MN02924A - - Google Patents

Download PDF

Info

Publication number
IN2012MN02924A
IN2012MN02924A IN2924MUN2012A IN2012MN02924A IN 2012MN02924 A IN2012MN02924 A IN 2012MN02924A IN 2924MUN2012 A IN2924MUN2012 A IN 2924MUN2012A IN 2012MN02924 A IN2012MN02924 A IN 2012MN02924A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Zhipei Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IN2012MN02924A publication Critical patent/IN2012MN02924A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2924MUN2012 2010-07-30 2012-12-31 IN2012MN02924A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36933510P 2010-07-30 2010-07-30
PCT/US2011/044926 WO2012015677A1 (en) 2010-07-30 2011-07-22 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-

Publications (1)

Publication Number Publication Date
IN2012MN02924A true IN2012MN02924A (enrdf_load_stackoverflow) 2015-06-12

Family

ID=44513148

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2924MUN2012 IN2012MN02924A (enrdf_load_stackoverflow) 2010-07-30 2012-12-31

Country Status (15)

Country Link
US (1) US8268836B2 (enrdf_load_stackoverflow)
EP (1) EP2598144B1 (enrdf_load_stackoverflow)
JP (1) JP5738412B2 (enrdf_load_stackoverflow)
KR (1) KR20130052740A (enrdf_load_stackoverflow)
CN (1) CN103002898A (enrdf_load_stackoverflow)
AR (1) AR085183A1 (enrdf_load_stackoverflow)
AU (1) AU2011282973B2 (enrdf_load_stackoverflow)
BR (1) BR112013002211A2 (enrdf_load_stackoverflow)
CA (1) CA2805494A1 (enrdf_load_stackoverflow)
EA (1) EA201270818A1 (enrdf_load_stackoverflow)
ES (1) ES2516940T3 (enrdf_load_stackoverflow)
IN (1) IN2012MN02924A (enrdf_load_stackoverflow)
MX (1) MX2013001247A (enrdf_load_stackoverflow)
TW (1) TWI431008B (enrdf_load_stackoverflow)
WO (1) WO2012015677A1 (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334581B (zh) * 2012-05-09 2018-02-02 伊莱利利公司 抗‑c‑Met抗体
CN103122000B (zh) 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10386376B2 (en) 2015-11-09 2019-08-20 Jeimei, Llc Sample container with integrated test strip
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ras gtp水解之組合物及其用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0619252A2 (pt) * 2005-11-30 2011-09-20 Vertex Pharma inibidores de c-met e seus usos
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CN101558070A (zh) * 2006-10-23 2009-10-14 Sgx药品公司 三唑并哒嗪蛋白激酶调节剂
DK2081937T3 (da) 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Triazolopyridazin-proteinkinasemodulatorer
PT2084162E (pt) 2006-10-23 2012-10-09 Sgx Pharmaceuticals Inc Triazoles bicíclicos como moduladores de proteína quinase
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EP2265614A1 (en) 2008-02-28 2010-12-29 Novartis AG Imidazo [1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease

Also Published As

Publication number Publication date
CA2805494A1 (en) 2012-02-02
EP2598144B1 (en) 2014-08-13
KR20130052740A (ko) 2013-05-23
AR085183A1 (es) 2013-09-18
JP5738412B2 (ja) 2015-06-24
AU2011282973A1 (en) 2013-01-10
AU2011282973B2 (en) 2014-03-20
ES2516940T3 (es) 2014-10-31
WO2012015677A1 (en) 2012-02-02
EA201270818A1 (ru) 2013-05-30
BR112013002211A2 (pt) 2016-05-24
CN103002898A (zh) 2013-03-27
WO2012015677A9 (en) 2012-12-13
TWI431008B (zh) 2014-03-21
MX2013001247A (es) 2013-03-18
EP2598144A1 (en) 2013-06-05
JP2013532687A (ja) 2013-08-19
TW201219393A (en) 2012-05-16
US8268836B2 (en) 2012-09-18
US20120028984A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
BR112013008959A2 (enrdf_load_stackoverflow)
BR112012030039A2 (enrdf_load_stackoverflow)
BR112012019354A2 (enrdf_load_stackoverflow)
BR112012028408A2 (enrdf_load_stackoverflow)
BR112012029986A2 (enrdf_load_stackoverflow)
BR112012027808A2 (enrdf_load_stackoverflow)
BR112012031500A2 (enrdf_load_stackoverflow)
BR112012017960A2 (enrdf_load_stackoverflow)
BR112013006400A2 (enrdf_load_stackoverflow)
BR112012031826A2 (enrdf_load_stackoverflow)
BR112012028186A2 (enrdf_load_stackoverflow)
BR112012016456A2 (enrdf_load_stackoverflow)
BR112012018256A2 (enrdf_load_stackoverflow)
BR112012027945A2 (enrdf_load_stackoverflow)
BR112013010949A2 (enrdf_load_stackoverflow)
BR112013003284A2 (enrdf_load_stackoverflow)
BR112013002646A2 (enrdf_load_stackoverflow)
IN2012MN02924A (enrdf_load_stackoverflow)
BR112012022788A2 (enrdf_load_stackoverflow)
BR112012016895A2 (enrdf_load_stackoverflow)
BR112012023446A2 (enrdf_load_stackoverflow)
BR112013006825A2 (enrdf_load_stackoverflow)
BR112012028859A2 (enrdf_load_stackoverflow)
BR112013007728A2 (enrdf_load_stackoverflow)
BR112012030078A2 (enrdf_load_stackoverflow)